An increased concentration of MUC5AC in the airways of lungs may play an important pathobiological role in the initiation and progression of COPD.
Preoperative use of a LAMA with a LABA was associated with significant improvements in lung function compared with use of LAMA alone in patients with lung cancer and COPD.
Using clinically important deterioration as a composite endpoint for disease progression may be beneficial in predicting long-term clinical outcomes in Japanese patients with COPD.
Metformin has demonstrated potential for slowing emphysema progression and its systemic consequences.
In patients with COPD, an enhanced pulmonary rehabilitation program that emphasizes chronic disease self-management may help to reduce physician visits.